BioCentury
ARTICLE | Analyst Picks & Changes

Analyst picks & changes

April 11, 1994 7:00 AM UTC

Magainin Pharmaceuticals Inc.

Hambrecht & Quist analyst Timothy Wilson downgraded Magainin Pharmaceuticals Inc. to "hold" from "buy" until the uncertainty over the development of MSI-78 is resolved. MAGN announced last week that the treatment and control groups in its pivotal Phase IIb/III study for impetigo showed the same 75 percent response rate (See April 5 BioCentury Extra). ...